US FDA’s Amy Abernethy Leaves Behind Legacy Of Tech Modernization, Real-World Data

After slightly more than two years as second-in-command, Abernethy tells the Pink Sheet she’s leaving FDA because the initiatives on which she was focused were starting to develop their own momentum. Abernethy, who also serves as the agency’s acting chief information officer, worked to modernize the FDA’s information technology infrastructure and data capabilities while also exploring ways to confidently use real-world data to support regulatory decision-making.

Amy Abernethy  2020
Amy Abernethy will depart the FDA in April after more than two years as principal deputy commissioner. • Source: FDA

Amy Abernethy’s decision to leave the US Food and Drug Administration after just more than two years boiled down to two reasons: wanting to see initiatives she helped establish move forward on their own, and having high confidence in the current acting commissioner.

Abernethy, the FDA’s principal deputy commissioner and acting chief information officer, will leave in mid- to late-April, the agency announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Real-World Evidence

More from Clinical Trials